Patents by Inventor Matteo Zacche?

Matteo Zacche? has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the preparation of enantiomerically pure norepinephrine
    Patent number: 11390579
    Abstract: The invention concerns a new, efficient process for the preparation of enantiomerically pure norepinephrine (also known as noradrenaline), or an addition salt thereof, using a catalytic hydrogenation system under hydrogen donor transfer. The invention also discloses a novel intermediate and the process for the preparation thereof.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: July 19, 2022
    Assignee: Edmond Pharma, s.r.l.
    Inventors: Matteo Zacche', Pier Andrea Gatti, Fulvio Gerli, Davide Sbarbada, Fabio Rondina
  • A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE NOREPINEPHRINE
    Publication number: 20220089520
    Abstract: The invention concerns a new, efficient process for the preparation of enantiomerically pure norepinephrine (also known as noradrenaline), or an addition salt thereof, using a catalytic hydrogenation system under hydrogen donor transfer. The invention also discloses a novel intermediate and the process for the preparation thereof.
    Type: Application
    Filed: April 2, 2020
    Publication date: March 24, 2022
    Applicant: Edmond Pharma, s.r.l.
    Inventors: Matteo Zacche', Pier Andrea Gatti, Fulvio Gerli, Davide Sbarbada, Fabio Rondina
  • POLYMORPHS OF X842
    Publication number: 20220002297
    Abstract: The present invention relates to polymorphs of 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (X842), more specifically forms A and B of X842. The invention also relates to a process for the preparation of these polymorphs, to pharmaceutical compositions comprising such polymorphs, and to methods for treating or preventing a gastrointestinal inflammatory disease or a gastric acid related disease, comprising administering a pharmaceutical composition comprising such polymorphs.
    Type: Application
    Filed: July 1, 2021
    Publication date: January 6, 2022
    Inventors: Mikael DAHLSTRÖM, Pingsheng HU, Davide SBARBADA, Matteo ZACCHÈ, Marinus BOUMA
  • Process for the resolution of medetomidine and recovery of the unwanted enantiomer
    Patent number: 8877941
    Abstract: A new and efficient process to obtain Medetomidine enantiomers, a selective and potent ?2-receptor agonist, is presented. Such process comprises a resolution step and a racemization reaction, to be able to recover the unwanted enantiomer which can be recycled as starting material.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: November 4, 2014
    Assignee: Edmond Pharma S.r.l.
    Inventors: Matteo Zacche', Fulvio Gerli, Pier Andrea Gatti
  • Process for the preparation of lurasidone hydrochloride
    Patent number: 8853395
    Abstract: Disclosed is a new and efficient process for the synthesis with high yields and purity of lurasidone hydrochloride, a medicament which is useful as a psychotropic substance. The process involves the preparation of lurasidone base in a reaction system not containing inorganic salts, followed by conversion of the latter to an addition salt with an organic carboxylic acid, which is finally converted to lurasidone hydrochloride.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: October 7, 2014
    Assignee: Edmond Pharma S.R.L.
    Inventors: Matteo Zacche', Fulvio Gerli, Pierandrea Gatti
  • PROCESS FOR THE PREPARATION OF LURASIDONE HYDROCHLORIDE
    Publication number: 20140243529
    Abstract: Disclosed is a new and efficient process for the synthesis with high yields and purity of lurasidone hydrochloride, a medicament which is useful as a psychotropic substance. The process involves the preparation of lurasidone base in a reaction system not containing inorganic salts, followed by conversion of the latter to an addition salt with an organic carboxylic acid, which is finally converted to lurasidone hydrochloride.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 28, 2014
    Applicant: EDMOND PHARMA s.r.l.
    Inventors: Matteo ZACCHE', Fulvio GERLI, Pierandrea GATTI
  • PROCESS FOR THE RESOLUTION OF MEDETOMIDINE AND RECOVERY OF THE UNWANTED ENANTIOMER
    Publication number: 20130225832
    Abstract: A new and efficient process to obtain Medetomidine enantiomers, a selective and potent ?2-receptor agonist, is presented. Such process comprises a resolution step and a racemisation reaction, to be able to recover the unwanted enantiomer which can be recycled as starting material.
    Type: Application
    Filed: February 26, 2013
    Publication date: August 29, 2013
    Applicant: Edmond Pharma s.r.l.
    Inventors: Matteo Zacche', Fulvio Gerli, Pier Andrea Gatti
  • Polymorphs of enantiopure erdosteine
    Patent number: 8269022
    Abstract: The present invention provides novel crystalline polymorphs of enantiopure Erdosteine, referred to as Form I and Form II, and processes for the preparation thereof.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: September 18, 2012
    Assignee: Edmond Pharma S.R.L
    Inventors: Pier Andrea Gatti, Matteo Zacche′, Massimo Nicola
  • POLYMORPHS OF ENANTIOPURE ERDOSTEINE
    Publication number: 20100249435
    Abstract: The present invention provides novel crystalline polymorphs of enantiopure Erdosteine, referred to as Form I and Form II, and processes for the preparation thereof.
    Type: Application
    Filed: November 10, 2008
    Publication date: September 30, 2010
    Applicant: Edmond Pharma S.R.L
    Inventors: Pier Andrea Gatti, Matteo Zacche', Massimo Nicola